How to manage the infectious risk under anti-TNF in inflammatory bowel disease.

摘要: The advent of biological therapy has had a significant impact on the management patients with inflammatory bowel disease. Nevertheless, anti-TNF-alpha agents are still used caution, driven by concerns about risk infection. Stringent post-marketing surveillance programmes and registries have allowed early recognition problems, highlighting an increased infectious complications. Although focus is drugs, other immunomodulators been less well scrutinised similarly carry considerable risks It remains unclear whether infection from anti-TNF any different conventional such as azathioprine or methotrexate, although it appears to be than that ascribed corticosteroids. majority concomitant immunosuppressive medication, which makes ascribing specific drug more difficult. life-threatening opportunistic infections associated obliged us re-consider methods prevention develop guidelines for risk-stratification diagnosis This encompasses vaccination chemoprevention, appropriate treatment underlying infection, patient education, travel advice careful monitoring whilst therapy. Contingency planning essential. Implementing these preventative strategies will appreciable organisation care current clinical practice.